Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Eli Lilly and Co | 37 |
Where innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 65 |
| 2 | A61K | Medicinal preparations | 46 |
| 3 | C07D | Heterocyclic compounds | 41 |
| 4 | C07B | General methods of organic chemistry | 21 |
| 5 | Y02P | Climate change mitigation: production | 15 |
| 6 | C07C | Acyclic and carbocyclic compounds | 14 |
| 7 | C07K | Peptides | 10 |
| 8 | Y02E | Climate change mitigation: energy | 3 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF SYNTHESIS OF PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS | 2011 | Eli Lilly and Co | 56 |
| COMBINATION THERAPY OF LASMIDITAN AND A CGRP ANTAGONIST FOR USE IN THE TREATMENT OF MIGRAINE | 2019 | Eli Lilly and Co | 13 |
| Pyridinoylpiperidines as 5-HT1F agonists | 2008 | Eli Lilly and Co | 22 |
| A kind of preparation method of 5-HT1F agonist compound | 2019 | 5 | |
| Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists | 2014 | Eli Lilly and Co | 7 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 17 |
| 2020 | 25 |
| 2021 | 24 |
| 2022 | 13 |
| 2023 | 11 |
| 2024 | 11 |
| 2025 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | John H. Krege | Eli Lilly (United States) | 18 |
| 2 | Mika Komori | Eli Lilly (Japan) | 11 |
| 3 | Erin Doty | Eli Lilly (United States) | 10 |
| 4 | Simin Baygani | Eli Lilly (United States) | 8 |
| 5 | Rashna Khanna | Eli Lilly (United Kingdom) | 6 |
| 6 | Ellen B. Dennehy | Purdue University West Lafayette | 6 |
| 7 | Helen Hochstetler | Eli Lilly (United States) | 5 |
| 8 | Louise Lombard | Eli Lilly (United States) | 5 |
| 9 | Joel Raskin | Eli Lilly (United States) | 5 |
| 10 | Li Shen Loo | Eli Lilly (United States) | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine | 2019 | 278 | Migraine and Headache Studies |
| Lasmiditan is an effective acute treatment for migraine | 2018 | 270 | Migraine and Headache Studies |
| Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study | 2012 | 188 | Migraine and Headache Studies |
| Gepants for the treatment of migraine | 2019 | 161 | Migraine and Headache Studies |
| Targeted 5-HT1F Therapies for Migraine | 2018 | 122 | Migraine and Headache Studies |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Lasmiditan HCl?
Who is the primary patent assignee for Lasmiditan, and how many patents do they hold?
What therapeutic indication is Lasmiditan HCl primarily studied for?
Which author has published the most papers on Lasmiditan HCl?
What is the dominant patent classification for Lasmiditan-related intellectual property?